share_log

Intelligent Bio Solutions | 8-K: Intelligent Bio Solutions Inc. Announces Preliminary Unaudited Fiscal Third Quarter and Nine-Month Revenue Results

Intelligent Bio Solutions | 8-K: Intelligent Bio Solutions Inc. Announces Preliminary Unaudited Fiscal Third Quarter and Nine-Month Revenue Results

Intelligent Bio Solutions | 8-K:Intelligent Bio Solutions Inc. 公布未经审计的第三财季初步收入和九个月收入业绩
美股sec公告 ·  04/18 16:33
Moomoo AI 已提取核心信息
Intelligent Bio Solutions Inc. reported a significant increase in preliminary unaudited revenue for both the fiscal third quarter and the nine months ending March 31, 2024. The company, which specializes in non-invasive drug testing technology, announced an 80% revenue increase for the quarter and a 193% increase for the nine-month period compared to the previous year. These results were driven by record cartridge sales since the acquisition of Intelligent Fingerprinting Limited in 2022. Cartridge sales rose by 17% and reader sales by 20% for the quarter, with a 25% and 63% increase, respectively, from July 1, 2023, to March 31, 2024. President and CEO Harry Simeonidis attributed the growth to the market's recognition of the need for comprehensive drug testing solutions in response to the rise of synthetic drugs. The company expects to release its full financial results for the quarter and nine-month period in its upcoming Quarterly Report on Form 10-Q, to be filed with the SEC in early May 2024.
Intelligent Bio Solutions Inc. reported a significant increase in preliminary unaudited revenue for both the fiscal third quarter and the nine months ending March 31, 2024. The company, which specializes in non-invasive drug testing technology, announced an 80% revenue increase for the quarter and a 193% increase for the nine-month period compared to the previous year. These results were driven by record cartridge sales since the acquisition of Intelligent Fingerprinting Limited in 2022. Cartridge sales rose by 17% and reader sales by 20% for the quarter, with a 25% and 63% increase, respectively, from July 1, 2023, to March 31, 2024. President and CEO Harry Simeonidis attributed the growth to the market's recognition of the need for comprehensive drug testing solutions in response to the rise of synthetic drugs. The company expects to release its full financial results for the quarter and nine-month period in its upcoming Quarterly Report on Form 10-Q, to be filed with the SEC in early May 2024.
Intelligent Bio Solutions Inc.报告称,第三财季和截至2024年3月31日的九个月未经审计的初步收入均大幅增加。该公司专门从事非侵入性药物测试技术,宣布与去年同期相比,本季度收入增长80%,九个月期间增长193%。这些业绩是由自2022年收购智能指纹有限公司以来的唱片盒销售推动的。从2023年7月1日至2024年3月31日,本季度墨盒销量增长了17%,阅读器销量增长了20%,分别增长了25%和63%。总裁兼首席执行官哈里·西蒙尼迪斯将增长归因于市场认识到需要全面的药物测试解决方案来应对合成药物的兴起。该公司预计将在2024年5月初向美国证券交易委员会提交的即将发布的10-Q表季度报告中发布本季度和九个月期间的完整财务业绩。
Intelligent Bio Solutions Inc.报告称,第三财季和截至2024年3月31日的九个月未经审计的初步收入均大幅增加。该公司专门从事非侵入性药物测试技术,宣布与去年同期相比,本季度收入增长80%,九个月期间增长193%。这些业绩是由自2022年收购智能指纹有限公司以来的唱片盒销售推动的。从2023年7月1日至2024年3月31日,本季度墨盒销量增长了17%,阅读器销量增长了20%,分别增长了25%和63%。总裁兼首席执行官哈里·西蒙尼迪斯将增长归因于市场认识到需要全面的药物测试解决方案来应对合成药物的兴起。该公司预计将在2024年5月初向美国证券交易委员会提交的即将发布的10-Q表季度报告中发布本季度和九个月期间的完整财务业绩。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息